|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBLN5 |
Gene summary for FBLN5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBLN5 | Gene ID | 10516 |
| Gene name | fibulin 5 | |
| Gene Alias | ADCL2 | |
| Cytomap | 14q32.12 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | A0A024R6G3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10516 | FBLN5 | C08 | Human | Oral cavity | OSCC | 4.75e-02 | 1.16e-01 | 0.1919 |
| 10516 | FBLN5 | C09 | Human | Oral cavity | OSCC | 6.73e-07 | 3.88e-01 | 0.1431 |
| 10516 | FBLN5 | NEOLP-1 | Human | Oral cavity | NEOLP | 1.88e-02 | 1.59e-01 | -0.0194 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000155831 | Oral cavity | NEOLP | regulation of cell growth | 73/2005 | 414/18723 | 1.23e-05 | 2.23e-04 | 73 |
| GO:007259332 | Oral cavity | NEOLP | reactive oxygen species metabolic process | 46/2005 | 239/18723 | 5.77e-05 | 7.77e-04 | 46 |
| GO:190040719 | Oral cavity | NEOLP | regulation of cellular response to oxidative stress | 21/2005 | 89/18723 | 3.74e-04 | 3.53e-03 | 21 |
| GO:200037731 | Oral cavity | NEOLP | regulation of reactive oxygen species metabolic process | 30/2005 | 157/18723 | 1.18e-03 | 8.72e-03 | 30 |
| GO:190288219 | Oral cavity | NEOLP | regulation of response to oxidative stress | 21/2005 | 98/18723 | 1.42e-03 | 1.01e-02 | 21 |
| GO:00194301 | Oral cavity | NEOLP | removal of superoxide radicals | 8/2005 | 23/18723 | 1.91e-03 | 1.29e-02 | 8 |
| GO:00850291 | Oral cavity | NEOLP | extracellular matrix assembly | 12/2005 | 45/18723 | 2.17e-03 | 1.42e-02 | 12 |
| GO:00714501 | Oral cavity | NEOLP | cellular response to oxygen radical | 8/2005 | 25/18723 | 3.46e-03 | 2.05e-02 | 8 |
| GO:00714511 | Oral cavity | NEOLP | cellular response to superoxide | 8/2005 | 25/18723 | 3.46e-03 | 2.05e-02 | 8 |
| GO:00003032 | Oral cavity | NEOLP | response to superoxide | 8/2005 | 28/18723 | 7.44e-03 | 3.73e-02 | 8 |
| GO:00003052 | Oral cavity | NEOLP | response to oxygen radical | 8/2005 | 29/18723 | 9.33e-03 | 4.43e-02 | 8 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBLN5 | SNV | Missense_Mutation | novel | c.743T>C | p.Met248Thr | p.M248T | Q9UBX5 | protein_coding | deleterious(0.03) | benign(0.077) | TCGA-A7-A13H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | PD |
| FBLN5 | SNV | Missense_Mutation | rs140452924 | c.1093N>G | p.Ile365Val | p.I365V | Q9UBX5 | protein_coding | tolerated(0.21) | possibly_damaging(0.785) | TCGA-EW-A1P3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
| FBLN5 | SNV | Missense_Mutation | rs760345539 | c.230N>A | p.Arg77Gln | p.R77Q | Q9UBX5 | protein_coding | tolerated(0.59) | possibly_damaging(0.705) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| FBLN5 | insertion | Frame_Shift_Ins | novel | c.1146_1147insCCTCTGTGGTCACGCTGCCTCCTCTTCCTCCTCTGTGTGT | p.Ile383ProfsTer19 | p.I383Pfs*19 | Q9UBX5 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| FBLN5 | insertion | Nonsense_Mutation | novel | c.1066_1067insAAGCCAGGAGTCTGAAATCAGTTTCACTGAGCTGAAATCCA | p.Val356GlufsTer12 | p.V356Efs*12 | Q9UBX5 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| FBLN5 | SNV | Missense_Mutation | novel | c.8N>A | p.Gly3Glu | p.G3E | Q9UBX5 | protein_coding | tolerated_low_confidence(0.15) | probably_damaging(0.972) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FBLN5 | SNV | Missense_Mutation | c.472G>A | p.Gly158Arg | p.G158R | Q9UBX5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| FBLN5 | SNV | Missense_Mutation | c.368N>G | p.Asn123Ser | p.N123S | Q9UBX5 | protein_coding | tolerated(0.25) | benign(0.026) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FBLN5 | SNV | Missense_Mutation | c.566C>A | p.Ser189Tyr | p.S189Y | Q9UBX5 | protein_coding | tolerated(1) | probably_damaging(0.995) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| FBLN5 | SNV | Missense_Mutation | novel | c.1061A>G | p.Asp354Gly | p.D354G | Q9UBX5 | protein_coding | tolerated(0.05) | possibly_damaging(0.677) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |